Opemalirsen clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses opemalirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- AZD2373 subcutaneous injection
- 2
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 2 |
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test opemalirsen.
- Oct 2027Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney DiseasePhase 2 · AstraZeneca
Studies
Open first, then newest update. How each study uses opemalirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney DiseaseActive, not recruitingPhase 2AstraZenecaNCT06824987Written as AZD2373-Arm 1
- Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)CompletedPhase 1AstraZenecaNCT07154901Written as Opemalirsen (AZD2373)
- A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African AncestryCompletedPhase 1AstraZenecaNCT05351047Written as AZD2373 subcutaneous injection
- A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.CompletedPhase 1AstraZenecaNCT04269031Written as AZD2373 subcutaneous injection
Codes
What other systems call opemalirsen · ClinicalTrials.gg INT017944
- UNII (FDA) SVT2GC4GOIOPEMALIRSENOne source FDA
- NCI Thesaurus C203038OpemalirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SVT2GC4GOI | OPEMALIRSEN | One source FDA |
| NCI Thesaurus | C203038 | Opemalirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.